Engineered immune cells take on lupus in early trial

NCT ID NCT07331467

Recruiting now Disease control Sponsor: Chongqing Precision Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial tests a new, fast-made CAR-T cell therapy for people with refractory systemic lupus erythematosus (SLE) who haven't improved with standard treatments. The therapy uses a patient's own immune cells, modified to target and attack lupus-causing cells. The study will enroll 18 participants to check safety and measure disease activity changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD19-targeted CAR-T cells
What this could lead to: If successful, this could offer a new treatment option for people with severe lupus that hasn't responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 18 participants, so results are preliminary. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Affiliated Drum Tower Hospital, Medical School of Nanjing University
RECRUITING

Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.